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In the twenty-first century, we have seen the (re-)emergence of several
RNA viruses causing severe infections in humans, like SARS and MERS
coronavirus, and more recently Ebola virus and Zika virus (ZIKV). A
problem with (re-)emerging virus infections is the lack of available
medical countermeasures, including antiviral treatment. Therefore, the
development of broadly acting antiviral compounds, as well as screening
of existing drugs for potential repurposing are explored as ways to fast-
track the drug development pipeline for emerging viral diseases. Here,
we briefly discuss the available information on potential antiviral treat-
ment of ZIKV infection, as well as specific challenges regarding use of
antivirals.
Zika virus is a positive-sense single-stranded RNA arbovirus that
belongs to the genus Flavivirus of the family Flaviviridae. Based on
nucleotide sequences, ZIKV can be further divided into an African
lineage and an Asian lineage. The main vector for ZIKV transmission
are Aedes mosquitoes. The first isolation of ZIKV was made in 1947
from serum of a febrile rhesus monkey in the Zika forest of Uganda.
During the twentieth century, sporadic human cases of ZIKV infection
were reported in Africa caused by the African lineage, and in Asia
caused by Asian lineage. The epidemiology of ZIKV changed dramati-
cally in the last decade, when major outbreaks of the Asian lineage of
ZIKV were reported on the Island of Yap in 2007 and in French
Polynesia in 2013. Subsequently, the Asian lineage of ZIKV spread to
the Americas in 2015.
The current outbreak of ZIKV shows new modes of transmission with
mother-to-fetus transmission and sexual transmission. Furthermore, in-
fectious ZIKV has been detected in breast milk, and there are concerns
of ZIKV transmission by blood products obtained from asymptomatic
viremic persons or by organ transplantation.
While postnatally acquired ZIKV infections are asymptomatic or
associated with mild symptoms, the recent outbreaks brought two
severe complications to light: a Guillain-Barre-like syndrome (GBS),
associated with paralysis, and microcephaly and other neuro-
developmental problems in infants born to women infected with ZIKV
during pregnancy. The rate of complications has been estimated to be
around 1/4000 cases for the GBS-like syndrome, and may be consid-
erably higher for the teratogenic effects, although much remains un-
known about the precise extent of the possible sequelae in fetuses and
infants. A significant contributing factor to this knowledge gap is that
up to 80 % of Zika virus infections may be asymptomatic, and these
‘silently’ infected women with potentially affected fetuses and babies
may go unnoticed.
There are currently no drugs approved for treatment, but several
nucleoside analogue drugs have some antiviral activity in cell culture
such as 2′-C-methylated nucleosides like 7-deaza-2′-C-methyladenosine
(7DMA) and 2′-C-methylcytidine (2CMC), and ribavirin, favipiravir,
and T-1105 (Fig. 1). In addition, 7DMA shows modest anti-ZIKV ac-
tivity in mice. Ribavirin and favipiravir are already approved for use as
antiviral drugs in humans for other indications, but showed less
in vitro antiviral effect against ZIKV than 7DMA. 7DMA and 2CMC
were initially developed for treatment of hepatitis C virus (HCV) which
is distantly related to ZIKV, and studies have shown that these com-
pounds have activity against other flaviviruses much more closely re-
lated to ZIKV like dengue virus (DENV). Of interest, other anti-HCV
nucleoside analogues like the approved sofosbuvir and mericitabine (in
clinical trials) also showed in vitro activity against DENV. GS-5734 and
BCX4430 are two very broad spectrum anti-RNA virus nucleoside ana-
logues that are currently in phase 1 and 2 clinical trials. According to
the manufacturer, BCX4430 reduced mortality in ZIKV-infected mice,
but this data has yet to be published.
The above shows that there is some evidence for the use of broad
spectrum antiviral drugs against ZIKV, in particular broad spectrum
nucleoside analogues, but the level of evidence thus far is insufficient
for licensed clinical applications. Also, a major challenge is how and
when such antiviral treatment would be applied, if available. The drug
should be active in cells of the nervous system; it should cross the
blood-brain-barrier and the placenta, and should be safe for pregnant
women, their fetuses, and infants, which are by no means trivial
concerns. For example, the unfavorable toxicity profile of ribavirin
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including teratogenicity limits its use to treat ZIKV infections in preg-
nant women. In addition, a lesson learned from treating other RNA
viruses is that monotherapy can cause the rapid emergence of resistant
viruses, stressing the need for development of drugs with different
modes of action to reduce the likelihood of selecting out resistant
strains.
Given the time needed to develop and approve new antiviral drugs,
clinicians are currently left empty handed in terms of targeted antiviral
treatment for ZIKV infection. A major lesson from this outbreak and
previous (re-)emerging RNA virus outbreaks is that we need safe, broad
spectrum antiviral drugs that can be tested rapidly in phase III clinical
trials during outbreaks to gain the time needed for the development of
other control and prevention measures, particularly vaccines.
Fig. 1. Replication mechanism of ZIKV and potential antiviral targets. Targets shown in the figure are known antiviral targets for
other flaviviruses and hepatitis C virus.
210 INVITED COMMENTARY
Compliance with Ethical Standards
Conflict of Interest
Noreen Mumtaz declares that she has no conflict of interest.
Jeroen J.A. van Kampen declares that he has no conflict of interest.
Chantal B.E.M. Reusken declares that she has no conflict of interest.
Charles A.B. Boucher declares that he has no conflict of interest.
Marion P.G. Koopmans declares that she has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Suggested Reading
http://www.nejm.org/page/zika-virus
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made.
Zika Virus: Where Is the Treatment? Mumtaz et al. 211
